KEEGO HARBOR, Mich., Oct. 05, 2021 (GLOBE NEWSWIRE) -- Zivo Bioscience, Inc. (NASDAQ: ZIVO, ZIVOW) (“ZIVO” and the “Company”), a biotech/agtech R&D company engaged in the development and commercialization of therapeutic, medicinal and nutritional product candidates originally derived from proprietary algal cultures, today issues a notice to its shareholders concerning the annual shareholder meeting.
Pursuant to the Notice previously provided for the Annual Meeting of Shareholders of Zivo Bioscience, Inc., ("Zivo" or the "Company") to be held on Tuesday, October 12, 2021, at 9:00 a.m. EST., the weblink for virtual attendance is provided below.
Weblink: https://agm.issuerdirect.com/zivo
Control ID for shareholder: For Shareholder Control IDs, Shareholders must refer to their proxy card received for their Control ID.
Control ID for other participants: 000000000 (* nine zeros)
(Note: for public health concerns regarding the coronavirus (COVID-19), the Annual Meeting will be held in a virtual format as well as in-person at 3600 Centerpoint Parkway, Pontiac, MI 48341.)
The Proxy Statement as filed is available at:
- https://ir.zivobioscience.com/all-sec-filings/content/0001654954-21-010024/zivo_def14a.htm?TB_iframe=true&height=auto&width=auto&preload=false
- as amended https://ir.zivobioscience.com/all-sec-filings/content/0001654954-21-010296/zivo_defa14a.htm?TB_iframe=true&height=auto&width=auto&preload=false
About Zivo Bioscience, Inc.
Zivo Bioscience, Inc. (NASDAQ: ZIVO) is a Michigan-based biotech/agtech company engaged in the investigation of the health and nutritional benefits of bioactive compounds derived from its proprietary algal cultures, and the development of natural bioactive compounds for use as dietary supplements and food ingredients, as well as biologically derived and synthetic candidates for medicinal and pharmaceutical applications in humans and animals, specifically focused on the general benefits of autoimmune and inflammatory response modulation. Visit zivobioscience.com to learn more.
Forward Looking Statements
Except for any historical information, the matters discussed herein contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Although ZIVO believes that we have a reasonable basis for each forward-looking statement, we caution you that these statements are based on a combination of facts and factors currently known by us and our expectations of the future, about which we cannot be certain. Our actual future results may be materially different from what we expect due to factors largely outside our control, including risks that our strategic partnerships may not facilitate the commercialization or market acceptance of our products; risks that our products may not be ready for commercialization in a timely manner or at all; risks that our products will not perform as expected based on results of our pre-clinical and clinical trials; our ability to raise additional funds; uncertainties inherent in the development process of our products; changes in regulatory requirements or decisions of regulatory authorities; the size and growth potential of the markets for our products; the results of clinical trials, our ability to protect our intellectual property rights and other risks, uncertainties and assumptions, including those described under the heading “Risk Factors” in our filings with the Securities and Exchange Commission. These forward–looking statements speak only as of the date hereof and ZIVO undertakes no obligation to revise or update any forward–looking statements for any reason, even if new information becomes available in the future.
Contacts:
Investor Relations
CORE IR
516-222-2560
Investor@zivobioscience.com
Media
CORE IR
Jules Abraham
917-885-7378
julesa@coreir.com
Source: Zivo Bioscience, Inc.
